Vizirgianakis Amends Stake in Apyx Medical Corp
Ticker: APYX · Form: SC 13D/A · Filed: May 9, 2024 · CIK: 719135
| Field | Detail |
|---|---|
| Company | Apyx Medical Corp (APYX) |
| Form Type | SC 13D/A |
| Filed Date | May 9, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: schedule-13d, beneficial-ownership, amendment
Related Tickers: APYX
TL;DR
Vizirgianakis updated their Apyx Medical stake filing. Watch for more details.
AI Summary
Stavros G. Vizirgianakis has filed an amendment (Amendment No. 1) to their Schedule 13D for Apyx Medical Corporation, dated May 7, 2024. This filing indicates a change in beneficial ownership of the company's common stock. The filing does not specify the exact number of shares or percentage of ownership change, but it is an update to a previous filing.
Why It Matters
This filing signals a potential shift in control or influence over Apyx Medical Corporation, which could impact the company's strategic direction and stock performance.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate significant shifts in a company's shareholder structure, potentially leading to activist investor involvement or strategic changes.
Key Players & Entities
- Stavros G. Vizirgianakis (person) — Filing party, beneficial owner
- Apyx Medical Corporation (company) — Subject company
- Fox Rothschild LLP (company) — Legal counsel for filing party
- Amy E. Culbert, Esq. (person) — Authorized contact for filing party
FAQ
What specific change in beneficial ownership is detailed in Amendment No. 1?
The filing is an amendment to a Schedule 13D and indicates a change in beneficial ownership, but the specific details of the change (e.g., number of shares, percentage) are not explicitly stated in the provided text excerpt.
When was the event requiring this Schedule 13D/A filing?
The date of the event which requires filing is May 7, 2024.
What is the CUSIP number for Apyx Medical Corporation's common stock?
The CUSIP number for Apyx Medical Corporation's Common Stock is 03837C106.
Who is authorized to receive notices and communications regarding this filing?
Amy E. Culbert, Esq. of Fox Rothschild LLP is authorized to receive notices and communications.
What was Apyx Medical Corporation formerly known as?
Apyx Medical Corporation was formerly known as BOVIE MEDICAL Corp and AN CON GENETICS INC.
Filing Stats: 954 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-05-09 07:45:22
Key Financial Figures
- $0.001 — ration (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securitie
Filing Documents
- ef20028689_sc13da.htm (SC 13D/A) — 43KB
- 0001140361-24-025058.txt ( ) — 45KB
is hereby amended to add the following
Item 4 is hereby amended to add the following: On May 7, 2024, Stavros Vizirgianakis entered into a letter agreement with APYX (the "Letter Agreement"). Pursuant to and immediately upon execution of the Letter Agreement, APYX agreed to appoint Mr. Vizirgianakis to its Board of Directors (the "Board") filling a vacancy created by the resignation and retirement of Andrew Makrides and agreed to appoint Mr. Vizirgianakis as Chair of the Board. APYX further agreed to cause the slate of director nominees standing for election and recommended by or on behalf of the Board to include Mr. Vizirgianakis for election at the 2024 Annual Meeting of Stockholders of APYX. Mr. Vizirgianakis and APYX also agreed to cooperate to identify and add an additional new director to the Board after six months from the date of the Letter Agreement, subject to certain terms and conditions. The terms of the Letter Agreement also provide that Mr. Vizirgianakis is subject to customary standstill obligations and mutual non-disparagement provisions with APYX until the close of the 2025 Annual Meeting of Stockholders of APYX and so long as Mr. Vizirgianakis remains a director of APYX. During the duration of the Letter Agreement, Mr. Vizirgianakis has agreed to vote in favor of the election of all the director nominees recommended for election by the Board and otherwise in accordance with the Board's recommendation on all other proposals, subject to certain limited exceptions. The foregoing description of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, which is referenced as Exhibit 99.1 hereto and is incorporated herein by reference. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
is hereby amended to add the following
Item 6 is hereby amended to add the following: As described in Item 4 of this Amendment No. 1 and incorporated herein by reference, on May 7, 2024, Mr. Vizirgianakis entered into the Letter Agreement with APYX. Page 3 of 5 Item 7. Material to be Filed as Exhibits.
is hereby amended to add the following
Item 7 is hereby amended to add the following: Exhibit No. Description 99.1 Letter Agreement, dated May 7, 2024 (incorporated by reference to Exhibit 10.1 to APYX's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2024 (File No. 001-31885). Page 4 of 5 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: May 9, 2024 /s/Stavros G. Vizirgianakis Stavros G. Vizirgianakis Page 5 of 5